Reuters logo
8 months ago
BRIEF-Oncoquest initiates commercial scale Oregovomab manufacturing program
December 7, 2016 / 10:16 PM / 8 months ago

BRIEF-Oncoquest initiates commercial scale Oregovomab manufacturing program

Dec 7 (Reuters) - Quest Pharmatech Inc

* Oncoquest initiates commercial scale Oregovomab manufacturing program for treatment of ovarian cancer

* Says additional phase ii clinical trial using Oregovomab in combination with a TLR3 agonist, hiltonol being initiated in U.S.

* Signs agreement with Cytovance for development of commercial scale antibody manufacturing, with Veristat for clinical trial management Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below